CohBar’s First Mitochondria Based Therapy Shows Promise In NASH

New Modality In Hard-To-Crack Field

 
• By Andrew McConaghie
  
Liver disease
Problems with safety and efficacy in various candidates mean that the US FDA has still not approved the first NASH therapy.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

More from Therapy Areas